Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524333 | 1.00 | KDM4E (0.56) | KDM4EPKMFKBP1ATAAR1NPC1 | |
| SCHEMBL523656 | 1.00 | KDM4E (0.56) | KDM4EPKMFKBP1ATAAR1NPC1 | |
| SCHEMBL10024995 | 0.84 | FKBP1A (0.50) | PKMFKBP1ATAAR1NPC1ALDH1A1 | |
| SCHEMBL541594 | 0.80 | NAAA (0.67) | — | |
| SCHEMBL515354 | 0.80 | NAAA (0.67) | — | |
| SCHEMBL9557074 | 0.79 | TAAR1 (0.68) | FKBP1ATAAR1NPC1ALDH1A1CACNA1F | |
| SCHEMBL522211 | 0.78 | FKBP1A (0.50) | PKMFKBP1ATAAR1NPC1ALDH1A1 | |
| SCHEMBL14610747 | 0.78 | FKBP1A (0.50) | PKMFKBP1ATAAR1NPC1ALDH1A1 | |
| SCHEMBL524499 | 0.78 | NPC1 (0.60) | KDM4EFKBP1ATAAR1NPC1ALDH1A1 | |
| SCHEMBL3020716 | 0.74 | PKM (0.64) | KDM4EPKMFKBP1ATAAR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| EP-2414529-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | Matrix Laboratories Ltd (IN) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010113175-A3 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | CES1, CMA1, CYP51A1 | KDM4E 254/4885PKM 559/4885FKBP1A 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.